Form 4: Intra-Cellular Therapies CFO Lawrence J. Hineline Reports Stock Sales

Lawrence J. Hineline, CFO of Intra-Cellular Therapies, Inc., reports the sale of common stock and conversion of restricted stock units, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 23, 2024, Lawrence J. Hineline converted 7,455 restricted stock units into common stock.
• On February 26, 2024, Hineline sold shares of Intra-Cellular Therapies common stock in multiple transactions at weighted average prices ranging from $68.33 to $70.15.
• Specifically, 300 shares were sold at $68.33, 6,867 shares at $69.38, and 288 shares at $70.15.
• Additionally, 5,882 shares were acquired through the exercise of stock options at $36.89 and then sold.
• Further sales of 600 shares occurred at weighted average prices of $69.47 and $69.81.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 14, 2023.
• The sales are intended to cover the reporting person's tax liability arising from the vesting of restricted stock units and the exercise of stock options.
• Following these transactions, Hineline still directly owns shares of Intra-Cellular Therapies common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading plan to cover tax liabilities. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan suggests these sales were pre-planned and not based on any specific non-public information.

Comparison to Industry Standards

• Monitoring insider transactions is a standard practice in financial analysis.
• Comparing the volume and frequency of insider sales to those of peers in the biotechnology industry can provide insights into management's sentiment and potential future performance.
• Companies like Amgen (AMGN) and Gilead Sciences (GILD) also have executives who regularly trade shares under 10b5-1 plans, and comparing the trading patterns can be informative.

Stakeholder Impact

• The stock sales by a key executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
• The transactions have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates